Introduction
Positron emission tomography (PET) is a noninvasive imaging modality for the in vivo visualization of various metabolic processes such as cellular proliferation, HSV1-tk reporter gene expression [1] [2] [3] , determination of receptor concentrations and the assessment of treatment response to therapy [4] [5] [6] . A paradigm for the non-invasive imaging of transgene expression involves the appropriate combination of a reporter gene and a reporter substrate or probe [7] . In essence, the reporter gene product selectively converts a reporter probe into a negatively charged metabolite that is trapped and accumulates within the transduced cells as it is unable to cross the cell membrane [3] . The accumulation of radioactivity within the transfected cell can be imaged by PET. The most studied reporter gene for the visualization of gene expression in animals and humans is herpes virus type 1 thymidine kinase (HSV1-tk) which is visualized by its enzyme product HSV1-TK. A number of 18 F-labeled pyrimidine ([ In recent years, [ 18 F]FEAU has emerged as a tracer with improved sensitivity and selectivity for imaging HSV1-tk expressing cells [13, 14] . Whereas purine [15] and pyrimidine [16] nucleoside analogues have found application as imaging agents for imaging HSV1-tk expression, cellular proliferation is mainly imaged with thymidine analogues [17] . The purine analogue, [ 18 F]FHBG, considered as the gold standard in clinical studies for HSV1-tk reporter gene imaging with PET [18, 19] exhibits high abdominal activity due to hepatobiliary elimination [20, 21] . When compared with pyrimidines, [ 18 F]FHBG shows less sensitivity towards the native HSV1-TK. We have previously reported on the synthesis, radiosynthesis and the in vivo evaluation of pyrimidine nucleoside analogues in which acyclic 6-(1,3-dihydroxyisobutyl) and 6-(1,3-dihydroxyisobutenyl) side chains have been attached at the C-6 position rather than at the N-1 position [22] [23] [24] . More pyrimidine based nucleosides for the development of novel fraudulent substrates of HSV-1 TK with improved pharmacodynamic and pharmacokinetic profile, we prepared a series of novel C-5 and N-1-substituted pyrimidine derivatives [26] . Among these series, a pyrimidine acyclonucleoside bearing a penciclovir (PCV)-like side chain, which was shown to be a substrate of HSV-1 TK, was selected as a lead compound for development as a PET imaging agent for measuring HSV-1 TK expression.
Here we report on the synthesis of unlabeled HHB-5-FEP and the radiosynthesis of its fluorine-18 labeled counterpart, HHB-5-[ 
Results and Discussion

Synthesis of the Reference HHB-5-FEP (7) and Precursor 8
The target compound, N-1- [4-hydroxy-3-(hydroxymethyl) butyl]-5-(2-fluoroethyl)pyrimidin-2,4-dione (HHB-5-FEP, 7) was prepared as outlined in Scheme 1.
Scheme 1.
Synthesis of reference compound HHB-5-FEP (7) and precursor 8. The introduction of penciclovir-like chain at N-1 position of pyrimidine scaffold was performed by reaction of 5-(2-acetoxyethyl)-4-methoxypyrimidin-2-one (1) with 4-acetoxy-(3-acetoxymethyl)butyl iodide (2) to give acyclic C-5-substituted pyrimidine derivative 3. Acetyl groups in both N-1 and C-5 side chains were then removed under basic conditions to give the triol 4 [27] . Protection of the 1,3-diols in penciclovir-like side chain was carried out using p-toluenesulfonic acid monohydrate (p-TsOH×H 2 O) and 2,2-dimethoxypropane to afford acetonide 5 in 59% chemical yield. Transformation of compound 5 to the fluorinated derivative 6 was achieved in a one-step reaction in 34% yield using diethylaminosulfur trifluoride (DAST) as fluorinating reagent. Initial attempts to prepare compound 7 from 6 using NaI, TMSCl in MeCN (Method A) afforded 7 in a somewhat lower yield (24%). Besides the formation of several by-products, purification of 7 also proved tedious. Method B which involves the use of concentrated acid provided target compound 7 in an optimal 29% yield.
In order to synthesize tosylate precursor 8 for the radiosynthesis of HHB- 
HHB-5-[
18 F]FEP was purified by a semipreparative radio-HPLC within 25 min (t R = 21.08 min) and formulated for in vitro and in vivo studies. The radiochemical yield was 45% ± 4, (n = 4) decay corrected. The total amount of radioactivity at the end of the synthesis (EOS) was up to 7.36 GBq in a radiochemical purity of > 99%. The specific activity ranged between 50 and 135 GBq/µmol after a total synthesis time of approx. 90 min. The chemical identity of HHB-5-[ 18 F]FEP was confirmed by coinjection with the non-radiolabeled reference compound HHB-5-FEP (7) . 3 OTs
Cell Uptake Studies
The in vitro uptake of HHB-5-[ 
Biodistribution
Similar to the in vitro cell uptake studies, a higher uptake of HHB-5-[ 18 F]FEP in TK-positive xenograft was observed compared to HEK293 control xenograft. The SUV PET for the TK-positive xenograft was 0.32. Uptake in the control xenograft was slightly higher (SUV PET = 0.17) compared to background activity (SUV PET The region with the highest uptake radioactivity was the abdomen followed by the gallbladder and the TK-positive xenograft. F ]FEP in TK-positive xenografts was significantly higher than in the control xenografts (p = 0.004 and 0.033, respectively, Student's t-Test). The uptake ratio of TK+ to control xenograft was 5.7 ± 1.9 for [ 
Experimental
General
Melting points (uncorrected) were determined with Kofler micro hot-stage (Reichert, Wien, Austria). Precoated Merck (Darmstadt, Germany) silica gel 60F-254 plates were used for thin layer chromatography and the spots were detected under UV light (254 nm). Column chromatography was performed using silica gel (0.063-0.2 mm) Fluka (Buchs, Switzerland); glass column was slurry-packed under gravity. Purification of the radiolabeled products was performed using a semi-preparative HPLC system, equipped with a Smartline Pump 1000, Smartline Manager 5000, Smartline UV detector 2500 (Knauer, city, state abbrev if US, country), 3 mL-loop and a GabiStar radiodetector (Raytest, Straubenhardt, Germany). A semi-preparative HPLC column with precolumn (Phenomenex, Gemini, C18, 110 Å, 5 µm, 250 × 10 mm) was used and UV absorption was monitored at 254 nm wavelength. For the purification of HHB-5-[ Specific activity was calculated based on the integrated UV peak by using a calibration curve, derived from different concentrations of the reference compound HHB-5-FEP and FHBG, respectively.
Cell Lines
Cell Culture
Cell uptake and internalization experiments were performed as previously described [25] . In brief, HEK293 human embryonic kidney cells and HEK293 stable transfected with nonmutant HSV1-tk (HEK293TK+ cells) were cultured in high glucose DMEM media supplemented with 10% FBS and 1% Penicillin/Streptomycin. Cells were grown in humidified atmosphere with 5% CO 2 at 37 °C. Thymidine kinase expression in the HEK293TK+ cells was maintained with 0.3 mg/mL G418 in the culture medium and was routinely verified by visualization of the cotransfected RFP with a fluorescence microscope. 3 mL) . The cells were resuspended in culture medium (0.7 mL), sedimented and lysed in lysis buffer (0.5 mL, 0.0625 M Tris, 2% sodium dodecyl sulfate, 7% glycerol, pH 6.8). The radioactivity of the cell lysate and the combined incubation medium were measured in a gamma counter (Wizard; PerkinElmer). Radioactivity of the cell lysates was normalized to total protein determined in cell lysate (50 μL) with the DC™ Protein Assay Kit I (BioRad, Hercules, CA). Data were expressed as percent accumulated activity/μg protein ((dpm cells × 100%/(dpm cells + dpm medium))/μg protein) and uptake ratios (dpm HEK293TK+/dpm HEK293 control), respectively [29] .
Animals
All animal experiments were approved by the local veterinarian department and complied with Swiss and local laws on animal protection. Six week-old female NMRI nude mice were purchased from Charles River Laboratories (Sulzfeld, Germany). Under 2-3% isoflurane anesthesia, animals were injected subcutaneously with 5 × 10 6 cells in Matrigel (100 µL). Transfected HEK293TK+ cells were injected on the right side of the shoulder region, control HEK293 cells on the left side. Xenograft growth and body weight were monitored regularly. Experiments were conducted when the xenografts reached a volume of 1-2 cm 3 , which was approx. four weeks after inoculation.
In Vivo PET Scan
For PET imaging, eXplore VISTA PET/CT tomograph (Sedecal/GE Healthcare, Madrid, Spain) was used. Nude mice, bearing HEK293TK+ xenografts on the right shoulder and HEK293 xenografts (control) on the left shoulder were injected with HHB-5-[ 18 
F]FEP or [
18 F]FHBG formulations (100 μL per injection) via lateral tail vein injection (t = 0). After injection of the radiotracer, mice were anesthetized by inhalation of isoflurane in an air/oxygen mixture approximately 5 min prior to PET data acquisition and scanned as described previously [30] . In dynamic PET mode, one animal was scanned from 0-90 min. For the second animal, data were acquired from 60-150 min p.i. For static PET scans, mice were scanned from 60-90 min. as it revealed to be the optimal time frame. After acquisition, PET data were reconstructed and fused datasets of PET and CT were analyzed with PMOD software (version 3.4). (4) were prepared according to a previously published procedure [27] .
Ex Vivo
Procedures for the Preparation of Compounds
N-1-[4-Acetoxy-3-(acetoxymethyl)butyl]-5-(2-acetoxyethyl)-4-methoxypyrimidin-2-one (3) and N-1-[4-hydroxy-3-(hydroxymethyl)butyl]-5-(2-hydroxyethyl)-4-methoxypyrimidin-2-one
N-1-[2-(2,2-Dimethyl-1,3-dioxane-5-yl)ethyl]-5-(2-hydroxyethyl)-4-methoxypyrimidin-2-one (5).
To a stirred solution of compound 4 (726 mg, 2.67 mmol) in dry DMF (9 mL), 2,2,-dimethoxypropane (0.61 mL, 3.89 mmol) and p-toluenesulfonic acid monohydrate (15.17 mg, 0.08 mmol) were added. The stirring was continued for 2 h at room temperature. The reaction mixture was then neutralized by triethylamine. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (CH 2 Cl 2 -CH 3 OH = 10:1) to give compound 5 as white crystals (494.7 mg, 59%, mp: 120-121 °C). (6) . A solution of compound 5 (296.7 mg, 0.95 mmol) in anhydrous CH 2 Cl 2 (7 mL) was cooled to −68 °C and diethylaminosulfur trifluoride (DAST) (0.27 mL, 2.04 mmol) was added under argon atmosphere. The reaction mixture was stirred at −40 °C for 3 h and then allowed to warm up to room temperature. The solvent was evaporated and the residue chromatographed (CH 2 Cl 2 -CH 3 OH = 15:1). Compound 6 was isolated as a colourless oil (100.2 mg, 34%). 
N-1-[2-(2,2-Dimethyl-1,3-dioxane-5-yl)ethyl]-5-(2-fluoroethyl)-4-methoxypyrimidin-2-one
N-1-[4-Hydroxy-3-(hydroxymethyl)butyl]-5-(2-fluoroethyl)pyrimidin-2,4-dione (HHB-5-FEP, 7).
Method A. To a solution of compound 6 (40 mg, 0.13 mmol) and MeCN (2 mL), trimethylsilyl chloride (TMSCl) (0.05 mL, 0.39 mmol) and NaI (39.5 mg, 0.26 mmol) were added under argon atmosphere. The mixture was stirred at reflux for 10 min, the solvent was evaporated under reduced pressure and the residue chromatographed (EtOAc-CH 3 OH = 10:1). Compound 7 was obtained as yellow oil (8.0 mg, 24%) .
Method B. Compound 6 (37.3 mg, 0.12 mmol) was dissolved in concentrated 37% HCl (1.6 mL) and the mixture was stirred at reflux for 10 min. Then, it was neutralized by the addition of 6 M NaOH. The salt was filtered of, the solvent was evaporated under reduced pressure and the residue chromatographed (CH 2 Cl 2 -CH 3 OH = 10:1). Compound 7 was obtained as colourless oil (9.0 mg, 29%). (8) . p-Toluenesulfonyl chloride (TsCl, 357 mg, 1.87 mmol) dissolved in pyridine (3 mL) was added to a cooled solution (0 °C) of compound 5 (100 mg, 0.32 mmol) in anhydrous pyridine (5 mL). The reaction mixture was stirred at 0 °C for 1 h then allowed to warm to room temperature and additionally stirred for 1 h. Ethyl acetate (50 mL) was added to the reaction mixture and the organic layer was extracted three times with water (2 × 30 mL). The aqueous washings were extracted again with ethyl acetate (2 × 30 mL) and the combined organic layer was dried over anhydrous MgSO 4 . The drying agent was filtered off, the solvent was removed by rotary evaporation and the residue chromatographed on silica gel (CH 2 Cl 2 -CH 3 OH = 15:1). Compound 8 was isolated as a colourless oil (102.2 mg, 68%). After cooling for 5 min, 5 M NaOH (1 mL) was added to neutralize the acidic solution and 0.6 M PBS (1.0 mL) and water (0.5 mL) were added for dilution to a total volume of 3 mL. The final radiolabeled product was purified by using a semi-preparative radio-HPLC. The product fraction was collected and passed through a sterile filter into a sterile pyrogen-free vial ready to use for further experiments. The specific activity ranged between 50 and 135 GB q/µmol. A chromatogram of the HPLC analysis of the formulated radiotracer is available in the Supplementary Materials. (30) (31) (32) (33) (34) (35) (36) (37) (38) . The solution was heated at 115 °C for 20 min and was allowed to cool down for 10 min. A mixture of 15% MeOH in CH 2 Cl 2 (1 mL) was added and the solution was passed through a Sep-Pak light silica (preconditioned with 5 mL Et 2 O). The reactor was additionally rinsed with 15% MeOH in CH 2 Cl 2 (3 mL) and the solution was also passed through the Sep-Pak light silica cartridge. The organic phase was evaporated to dryness under reduced pressure and a gentle stream of nitrogen at 90 °C. For deprotection, 1 M hydrochloric acid (0.6 mL) was added to the reaction vessel and the solution was heated for 10 min at 115 °C to give [ 18 F]FHBG. After cooling for 5 min, 1 M NaOH (0.6 mL) was added to neutralize the acidic solution. Then, 0.6 M PBS (1 mL) and water (0.8 mL) were added for dilution to a total volume of 3 mL. The radioproduct was purified by using a semi-preparative radio-HPLC. The product fraction was collected and passed through a sterile filter into a sterile pyrogen-free vial.
N-1-[2-(2,2-Dimethyl-1,3-dioxane-5-yl)ethyl]-5-[2-((p-toluenesulfonyl)oxy)ethyl]-4-methoxy-pyrimidin-2-one
Conclusions
The novel N-acyclic 5-(2-fluoroethyl)pyrimidine nucleoside analogue, HHB-5-FEP, was synthesized in a five-step reaction sequence starting from 5-(2-acetoxyethyl)-4-methoxypyrimidin-2-one. Synthesis of its 18 F labeled structural analogue, HHB-5-[ 
